Kromek turns maiden profit as it predicts further sustained growth

Kromek Group PLC reported its maiden pre-tax profit of £3.1 million for the fiscal year ending April 30, a significant turnaround from a £3.5 million loss, driven by a 37% revenue increase to £26.5 million and exceeding market expectations. This performance was primarily fueled by a landmark $37.5 million contract with Siemens Healthineers, bolstering its Advanced Imaging division, alongside substantial debt reduction of over £11 million. The company projects continued profitability and higher revenue for 2026, anticipating growth across both its Advanced Imaging and rebounding CBRN Detection divisions.

Analysis

Kromek Group PLC (AIM:KMK) has reached a significant inflection point, reporting its maiden pre-tax profit of £3.1 million, a stark reversal from the prior year's £3.5 million loss and a figure that surpassed market expectations. This turnaround was underpinned by robust top-line growth, with revenue climbing 37% to £26.5 million. The primary catalyst was the Advanced Imaging division, where sales more than doubled to £20.3 million, largely driven by a landmark $37.5 million contract with Siemens Healthineers, of which $25 million was recognized in the fiscal year. While the CBRN detection business experienced a weak first half due to government order delays linked to UK and US elections, it demonstrated a strong second-half recovery, securing a £2 million deal with the UK Ministry of Defence and an additional £2.9 million in international orders post-year-end. Crucially, the company has substantially de-risked its balance sheet by repaying over £11 million in loans, leaving it with £1.7 million in cash, supplemented by a post-period $5 million payment and an undrawn £6 million credit facility. Management's guidance for fiscal 2026 projects continued profitability and higher revenue, with strong growth anticipated in the rebounding CBRN segment and like-for-like growth in Advanced Imaging, signaling confidence in sustained operational performance.

Key Decisions for Investors

• Given the company has achieved its first-ever profit and beaten market expectations, investors should re-evaluate the stock's valuation, as this may trigger a re-rating from a speculative to a growth-oriented investment profile.
• Closely monitor the contract pipeline and revenue conversion in the CBRN division, as its strong second-half rebound and post-period orders are critical for meeting the guided strong year-on-year growth and diversifying revenue beyond the key Siemens contract.
• The significantly improved balance sheet, with substantial debt reduction and ample liquidity, mitigates financing risk and provides capital for expansion, which should be factored into assessments of the company's long-term growth capacity and stability.
• Consider the revenue visibility provided by the multi-year Siemens contract as a core pillar of the investment thesis, while also noting the inherent sensitivity of the CBRN segment to the timing of government procurement cycles.